What is HC Wainwright’s Estimate for Precigen Q4 Earnings?

Precigen, Inc. (NASDAQ:PGEN) – Analysts at HC Wainwright lifted their Q4 2026 earnings per share estimates for shares of Precigen in a note issued to investors on Wednesday, August 5th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of $0.06 per share for the quarter, up from their previous estimate of $0.04. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.02) per share. HC Wainwright also issued estimates for Precigen’s Q1 2027 earnings at $0.08 EPS, Q2 2027 earnings at $0.10 EPS, Q3 2027 earnings at $0.12 EPS, Q4 2027 earnings at $0.14 EPS, FY2027 earnings at $0.44 EPS, FY2028 earnings at $0.71 EPS and FY2030 earnings at $1.49 EPS.

Other equities analysts also recently issued reports about the company. Citigroup reiterated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. Citizens Jmp upped their price objective on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research note on Thursday, May 14th. Finally, Wall Street Zen lowered shares of Precigen from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $14.50.

Precigen Price Performance

Shares of NASDAQ:PGEN opened at $6.89 on Thursday. The company has a market cap of $2.46 billion, a P/E ratio of -6.62 and a beta of 1.02. The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62. Precigen has a 52 week low of $1.70 and a 52 week high of $7.23. The business has a fifty day simple moving average of $5.12 and a 200-day simple moving average of $4.46.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Precigen had a positive return on equity of 484.64% and a negative net margin of 183.98%.The company had revenue of $54.98 million for the quarter, compared to analyst estimates of $27.98 million. The company’s quarterly revenue was up 6322.7% on a year-over-year basis.

Institutional Trading of Precigen

Institutional investors have recently modified their holdings of the company. State of Wyoming acquired a new stake in Precigen during the 1st quarter worth approximately $27,000. NBC Securities Inc. purchased a new position in Precigen in the fourth quarter valued at approximately $38,000. Caitong International Asset Management Co. Ltd acquired a new position in Precigen during the third quarter valued at approximately $39,000. Royal Bank of Canada lifted its position in Precigen by 102.6% during the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,426 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in Precigen during the third quarter valued at approximately $41,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Insider Transactions at Precigen

In other Precigen news, CEO Helen Sabzevari sold 346,836 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the completion of the sale, the chief executive officer owned 3,768,872 shares of the company’s stock, valued at approximately $22,198,656.08. The trade was a 8.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Donald P. Lehr sold 29,131 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $4.36, for a total value of $127,011.16. Following the sale, the insider directly owned 755,461 shares of the company’s stock, valued at approximately $3,293,809.96. This trade represents a 3.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 956,500 shares of company stock worth $5,248,371 over the last ninety days. 41.40% of the stock is owned by insiders.

Precigen News Roundup

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong Q2 results: Precigen reported $54.98 million in revenue, far above the roughly $28 million analyst estimate, and earnings of $0.05 per share versus expectations for a loss. Revenue increased more than 6,300% year over year, while PAPZIMEOS generated $53.1 million in quarterly net revenue. Precigen Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Commercial momentum and cash outlook: PAPZIMEOS patient-hub enrollment exceeded 500 patients, and the FDA granted the product seven years of market exclusivity. Precigen said product proceeds and its $38.7 million in cash, equivalents and investments are expected to support cash-flow break-even by the end of 2026. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: HC Wainwright raised its outlook: The firm reiterated a Buy rating and $18 price target while increasing EPS estimates for Q4 2026, every quarter of 2027, FY2027 to $0.44 from $0.34, and FY2030 to $1.49 from $1.44. The revisions indicate expectations for a faster transition to sustained profitability.
• Neutral Sentiment: Trading activity remains elevated: Precigen was reported to be the target of unusually large options activity, which may amplify short-term volatility without clearly indicating the direction of the stock.
• Negative Sentiment: Insider selling is a risk: Reported insider activity over the past six months consisted of sales only, including substantial selling by executives and major shareholder Randal J. Kirk. Such transactions may weigh on sentiment, although they do not necessarily reflect the company’s operating outlook.
• Negative Sentiment: One estimate was trimmed: HC Wainwright lowered its FY2028 EPS forecast slightly to $0.71 from $0.72, a modest offset to the broader upward revisions.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.